Biotech stocks have fallen to earth with a thud in 2021 after soaring last year amid excitement over the development of Covid-19 vaccines, dealing big losses to some hedge funds.
The sector is being buffeted by concerns Congress will move to put a lid on drug pricing and a surfeit of early-stage biotech shares as the IPO market booms.
America’s immigration debate has taken a nativist flip. Think about 2016, when then-candidate Donald Trump acquired fierce pushback for his…
Let’s face it: power ache is a depressing actuality for hundreds of…
Berg Perception, the world’s main IoT market analysis supplier, at present launched…
OPINION: Whoppers. Those are what President Biden tells, according to…
